Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Wake Forest University National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00068276 |
RATIONALE: Cholecalciferol (vitamin D) may improve quality of life by increasing blood counts, decreasing fatigue, and improving other symptoms of myelodysplastic syndrome.
PURPOSE: This phase II trial is studying how well cholecalciferol works in treating patients with myelodysplastic syndrome.
Condition | Intervention | Phase |
---|---|---|
Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases |
Drug: cholecalciferol |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | Orthomolecular Vitamin D3 in Low-Risk Myelodysplastic Syndrome: An Open-Label Clinical Trial |
Study Start Date: | July 2003 |
OBJECTIVES:
OUTLINE: This is an open-label, pilot study.
Patients receive oral cholecalciferol once daily. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed myelodysplastic syndromes (MDS)
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
United States, North Carolina | |
Comprehensive Cancer Center at Wake Forest University | |
Winston-Salem, North Carolina, United States, 27157-1082 |
Study Chair: | Istvan Molnar, MD | Wake Forest University |
Investigator: | Bayard L. Powell, MD | Wake Forest University |
Study ID Numbers: | CDR0000318802, CCCWFU-29203, CCCWFU-BG03-117 |
Study First Received: | September 10, 2003 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00068276 |
Health Authority: | United States: Federal Government |
previously treated myelodysplastic syndromes de novo myelodysplastic syndromes secondary myelodysplastic syndromes |
atypical chronic myeloid leukemia myelodysplastic/myeloproliferative disease, unclassifiable childhood myelodysplastic syndromes |
Myelodysplastic syndromes Cholecalciferol Precancerous Conditions Chronic myelogenous leukemia Hematologic Diseases Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Myelodysplasia Myelodysplastic Syndromes Ergocalciferols Myeloproliferative Disorders |
Leukemia, Myeloid Myelodysplastic myeloproliferative disease Leukemia Preleukemia Vitamin D Leukemia, Myelogenous, Chronic, BCR-ABL Positive Neoplasm Metastasis Myelodysplastic-Myeloproliferative Diseases Bone Marrow Diseases |
Neoplasms Pathologic Processes Disease Neoplasms by Histologic Type Growth Substances Vitamins |
Syndrome Physiological Effects of Drugs Bone Density Conservation Agents Micronutrients Pharmacologic Actions |